Topotecan HCl

製品コードS1231 別名:NSC609699, Nogitecan HCl, SKFS 104864A

Topotecan HCl化学構造

分子量(MW):457.91

Topotecan HClは一種のトポイソメラーゼI阻害剤ですが、無細胞試験でMCF-7 Luc細胞とDU-145 Luc細胞に作用する時のIC50値が13nMと2nMにそれぞれ分かれます。

サイズ 価格(税別) 在庫  
JPY 29880.00 あり
JPY 53120.00 あり

カスタマーフィードバック(2)

  • Cells were treated at the same concentrations as in Caspase3/7 assay for 16 hours and total cell lysates were prepared for Western blotting. GAPDH was used as a loading control.

    BMC Cancer, 2015, 10.1186/s12885-015-1231-z. Topotecan HCl purchased from Selleck.

    Pax3:Foxo1a knockdown increases select chemotherapy sensitivities. MTS assay was performed for Pax3:Foxo1a knockdown mouse aRMS tumor cells treated with DNA damaging agents and microtubule inhibitors. Pax3:Foxo1a knockdown reduced the concentration at which viability was impaired by 50% (IC50) of topotecan by 4.8 fold, respectively, yet did not affect the IC50 of mafosfamide.

    PLoS Genet 2014 10(1), e1004107. Topotecan HCl purchased from Selleck.

製品安全説明書

Topoisomerase阻害剤の選択性比較

生物活性

製品説明 Topotecan HClは一種のトポイソメラーゼI阻害剤ですが、無細胞試験でMCF-7 Luc細胞とDU-145 Luc細胞に作用する時のIC50値が13nMと2nMにそれぞれ分かれます。
特性 Topotecan is a water-soluble derivative of camptothecin.
ターゲット
Topo I (DU-145 Luc cells) [1]
(Cell-free assay)
Topo I (MCF-7 Luc cells) [1]
(Cell-free assay)
2 nM 13 nM
体外試験

Stronger drug activity of Topotecan is observed for DU-145 Luc and MCF-7 Luc cells. [1] Topotecan causes cytotoxicity during the course of DNA replication by stabilizing the covalent complex between topoisomerase I and DNA and preventing the religation of enzyme-linked single-strand DNA break. Topotecan stabilizes topoisomerase I/DNA cleavable complexes in radiation-resistant human B-lineage acute lymphoblastic leukemia (ALL) cells, causes rapid apoptotic cell death despite high-level expression of bcl-2 protein, and inhibits ALL cell clonogenic growth in a dose-dependent fashion. [2]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human MDA-MB-435 cells Mnv6R5l1d3SxeHnjxsBie3OjeR?= MXW3NkBp MnjBR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDpZ|UxRTFibl2= NFO4W3YzODN5MUG4Ny=>
human Bel7402 cells Mmq1R5l1d3SxeHnjxsBie3OjeR?= M1KyTVk3KGh? NIXYephEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBD\Wx5NECyJINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OS5{IH7N MXuxOVE3PTF2NB?=
human HCT8 cells NUG3b|QzS3m2b4TvfIlkyqCjc4PhfS=> M4LtOVk3KGh? MV;DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3Q5KGOnbHzzJIFnfGW{IEm2JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MT61JI5O M{PxOFE2OTZ3MUS0
human MCF7 cells MlfwR5l1d3SxeHnjxsBie3OjeR?= Mm\MPVYhcA>? NVu0OolRS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEvQCCwTR?= MY[xOVE3PTF2NB?=
human A549 cells Mmf0R5l1d3SxeHnjxsBie3OjeR?= NX3jPWR1QTZiaB?= NXX4RZV{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA6PiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVMvOiCwTR?= Mn;QNVUyPjVzNES=
human colon carcinoma SW620 cell MnjIR5l1d3SxeHnjxsBie3OjeR?= NHT6V3FEgXSxdH;4bYMheG:2ZX70bYF1cW:wIH;mJHRweG:2ZXPhckApXFBrIHL5JJRp\SClb33wc5Vv\CCrbjDoeY1idiClb3zvckBk[XKlaX7vcYEhW1d4MkCgZ4VtdCCuaX7lMEBKSzVyPUOuNkBvVQ>? NGXsVZgyOjRyOEewOy=>
human MESSA cells MmD4R5l1d3SxeHnjxsBie3OjeR?= M1PCdFczKGh? NXP0[VV[S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVU1GgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwQVQhdk1? MkX3NlE{PDF4N{S=
human BGC823 cells NGLMRXFEgXSxdH;4bYPDqGG|c3H5 NIrKNJI6PiCq NEKyc49EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBDT0N6MkOgZ4VtdHNiYX\0[ZIhQTZiaILzJIJ6KE2WVDDhd5NigSxiSVO1NF01NjNibl2= M4D5blE2OTZ3MUS0
human Ketr3 cells MWTDfZRwfG:6aXRCpIF{e2G7 NV\Qb5NnQTZiaB?= M1vj[GN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmfHJ|IHPlcIx{KGGodHXyJFk3KGi{czDifUBOXFRiYYPzZZktKEmFNUC9OE46KG6P M3LtSVE2OTZ3MUS0
LOX cells NGjOeVJEgXSxdH;4bYPDqGG|c3H5 NEj1RVJEgXSxdH;4bYNqfHlid3HzJIRmfGW{bXnu[YQhcW5idnn0do8hcW5iTF;YJINmdGy|IDjt[Yxidm:vYTmgc4YhcHWvYX6geJVud3JiY3XscEBtcW6nczDifUB2e2mwZzDNWHQh[XO|YYmsJGlEPTB;NTDuUS=> M2P3N|c5PTN|M{G=
human A549 cells MVPGeY5kfGmxbjDhd5NigQ>? NV3ibGxFPCCq MmTIRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:PSCwTR?= MWmxPFIxPzd2OB?=
human H69 cells NF2wWGZEgXSxdH;4bYPDqGG|c3H5 MlLKO|IhcA>? MmD1R5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTFY6KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDhcIFu[XJiYnz1[UBie3OjeTygTWM2OD14IH7N NXf4U5dQOjF|NEG2O|Q>
human A2780 cells NWi2W5BES3m2b4TvfIlkyqCjc4PhfS=> NYH4eIV{PzJiaB?= MVfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDBNlc5OCClZXzsd{BwfmW{ZYjwdoV{e2mwZzDhcJBp[TWkZYThN{BqdnSnZ4LpckBie3Onc4Pl[EBieyClZXzsJJN2en[rdnHsJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTB;NjDuUS=> M1v0TFIzQTV7MkS2
human LNCAP cells NVjJcmU6S3m2b4TvfIlkyqCjc4PhfS=> M{nw[VczKGh? M3zmW2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxPS0GSIHPlcIx{KGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME25JI5O MnHtNlE{PDF4N{S=
human HOP62 cells NVXHdpFtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWfHdo94fGhiaX7obYJqfGmxbjDv[kBpfW2jbjDIU3A3OiClZXzsd{BjgSCoaY\lMYRwe2ViZ4Lve5RpKGmwaHnibZRqd25iYYPzZZktKEmFNUC9NVAhdk1? NFPFV4czPTlyOUK3PS=>
human MCF7 cells NGLRUVNIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M3\1O2dzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJG1ETjdiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCLQ{WwQVExKG6P NWnYbYUzOjV7MEmyO|k>
human UACC62 cells Mnz5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NWjKc5lET3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4hXUGFQ{[yJINmdGy|IHL5JIZqfmVvZH;z[UBoem:5dHigbY5pcWKrdHnvckBie3OjeTygTWM2OD1zMDDuUS=> NHL4SIYzPTlyOUK3PS=>
human DU145 cells NYXT[oxIT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHXuTm5Iem:5dHigbY5pcWKrdHnvckBw\iCqdX3hckBFXTF2NTDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFnDOVA:OTBibl2= MlLiNlU6ODl{N{m=
LoVo cell line NE\mR4FEgXSxdH;4bYPDqGG|c3H5 MXPDfZRwfG:6aXOgdI91\W62aXH0bY9vKG:oIGTvdI91\WOjbjCoWHAqKGK7IITo[UBkd22yb4Xu[EBqdiBqaIXtZY4h[2:ub4LlZ5RidCClYX7j[ZIhVG:YbzDj[YxtKGyrbnWsJGlEPTB;MUGuOkBvVQ>? M3j2WlEzPDB6N{C3
human lymphoblast tumor cell line RPM18402 M1Lzb2N6fG:2b4jpZ:Kh[XO|YYm= MUHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDsfY1xcG:kbHHzeEB1fW2xcjDj[YxtKGyrbnWgVnBOOTh2MEKsJGlEPTB;MUKgcm0> MmLxNVI{QTJ5NEW=
human HL60 cells NYixO4N4TnWwY4Tpc44h[XO|YYm= MkH3RY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFy2NEBk\WyuczDifUBUWkJibXX0bI9lNCCLQ{WwQVEzKG6P NIrI[IkyQTV2MUS4Ny=>
human A375 cells MlLJR5l1d3SxeHnjxsBie3OjeR?= M3TxTlczKGh? MnzPR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVM4PSClZXzsd{Bi\nSncjC3NkBpenNiYomgZYxidWG{IHLseYUh[XO|YYmsJGlEPTB;MUOgcm0> NVPye4xDOjF|NEG2O|Q>
COR-L23/P cell M2\iNGN6fG:2b4jpZ:Kh[XO|YYm= NW\BU444S3m2b4TvfIlkcXS7IH3lZZN2emWmIIXzbY5oKHSqZTDDU3IuVDJ|IIDhdoVvfGGuIDjDU3IuVDJ|L2CpJIh2dWGwIH7vckB{dWGubDDj[YxtKGy3bnegZ4Fz[2mwb33hJINmdGxibHnu[UwhUUN3ME2xN{4zKG6P M1[1O|EyQDB4N{K0
human NCI-H460 cells MVTQdo9tcW[ncnH0bY9vKGG|c3H5 MUm3NkBp Ml7aRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCQQ1mtTFQ3OCClZXzsd{Bi\nSncjC3NkBpenNiYomgZ492dHSncjDjc5VvfGW{IHHuZYx6e2m|LDDJR|UxRTF4IH7N NX3CNXZvOjF5OEOzOlk>
human MOLT4 cells M{\SV2N6fG:2b4jpZ:Kh[XO|YYm= MY[3NkBp NHrERolEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOV0yWNDDj[YxteyCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwQVE6KG6P MVmyOFkxODd{NR?=
human LoVo cells MlW5R5l1d3SxeHnjxsBie3OjeR?= NV\pVFVyPzJiaB?= M2WzWmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGxwXm9iY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2yNEBvVQ>? M2fzWVIxOzdzMUiz
RPM18402 tumor cell line NVLXS4hKWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3jKfmNwdmOnboTyZZRqd25icnXxeYlz\WRidH:gbY5pcWKrdDDj[YxtKHC{b3zp[oVz[XSrb36gbY4hWlCPMUi0NFIhfHWvb4KgZ4VtdCCuaX7lMEBKSzVyPUKwJI5O Mnn3NVU1QDJ7Mkm=
human SN12C cells NG\tUnRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlLtS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gV24yOkNiY3XscJMh[nliZnn2[U1ld3OnIHfyc5d1cCCrbnjpZol1cW:wIHHzd4F6NCCJSUWwQVIxKG6P M2C0clI2QTB7Mke5
human RPMI8226 cells M3L5e2N6fG:2b4jpZ:Kh[XO|YYm= NETkXJREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBTWE2LOEKyOkBk\WyuczDifUBOXFRibXX0bI9lNCCLQ{WwQVIyKG6P NILFcHMyQTBzMkm5Oi=>
HT-29 cells Mke5R5l1d3SxeHnjxsBie3OjeR?= MnXFR5l1d3SxeHnjbZR6KHejczDk[ZRmem2rbnXkJIlvKH[rdILvJIlvKEiWLUK5JINmdGy|KHPvcI9vMSCxZjDoeY1idiC2dX3vdkBk\WyuIHzpcoV{KGK7IIXzbY5oKE2WVDDhd5NigSxiSVO1NF0zPSCwTR?= MX:3PFU{OzNz
SK-BR-3 cells MVnDfZRwfG:6aXRCpIF{e2G7 NUW3dlg2UW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4h[nKnYYP0JINidmOncjDj[YxtKGyrbnWgLHNMNUKULUOpMEBKSzVyPUK2JI5O M4fQXlEyOzN2NU[5
HeLa cells MX7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVTFbJZET3Kxd4ToJIlvcGmkaYTpc44hd2ZiSHXMZUBk\WyuczDh[pRmeiB2IHThfZMtKEeLNUC9N|Ahdk1? MnTJNVc1OTh3OEK=
UACC 62 cells MVjDfZRwfG:6aXRCpIF{e2G7 M3j2SXRme3SnZDDpckB3cXS{bzDmc5Ih[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hfHWvb4KgZ4VtdCCuaX7lJHVCS0NiNkKgLI1mdGGwb33hLUwhT0l3ME2zNEBvVQ>? MXuxNFcyPDVyMh?=
human HCT116 cells MlmzS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M13qRWdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGhEXDFzNjDj[YxteyCkeTDmbZZmNWSxc3Wg[5Jwf3SqIHnubIljcXSrb36gZZN{[XluIFfJOVA:OzBibl2= NXezSGVwOjV7MEmyO|k>
human lung cancer cell line (H128) NIGwZmZEgXSxdH;4bYPDqGG|c3H5 NFS5eWRKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBtfW6pIHPhcoNmeiClZXzsJIxqdmViKFixNlgqNCCLQ{WwQVMyKG6P M3TheVEyOzN2NU[5
human MES-SA/Dx5 cells MkKyR5l1d3SxeHnjxsBie3OjeR?= NUfZZW84S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUWVLWPBM2R5PSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDNSHIyKGGodHXyJFczKGi{czDifUBidGGvYYKgZox2\SCjc4PhfUwhUUN3ME2zN{BvVQ>? M3Sx[lIyOzRzNke0
human A2780 cells NF\KbXFEgXSxdH;4bYPDqGG|c3H5 NGPhVGI4OiCq MoHnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVI4QDBiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2zN{BvVQ>? M4fNT|I1QTByN{K1
human MDA-MB-435 cells M1TiPWN6fG:2b4jpZ:Kh[XO|YYm= MUW3NkBp MlfIR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUWRCNU2ELUSzOUBk\WyuczDpcoN2[mG2ZXSg[o9zKDd{IHjyd{BjgSCPVGSgZZN{[XluIFfJOVA:OzRibl2= M1SyPVIzQDZ5MEG5
human stomach cancer cell line (MKN45) NXG5ZpROS3m2b4TvfIlkyqCjc4PhfS=> M160ZmlvKF[rdILvJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJJN1d22jY3igZ4Fv[2W{IHPlcIwhdGmwZTCoUWtPPDVrLDDJR|UxRTN6IH7N M{DlNFEyOzN2NU[5
human KB3-1 cells NUHEPXpwS3m2b4TvfIlkyqCjc4PhfS=> MVrDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRlMuOSClZXzsd{Bi\nSncjDNWHQh[XO|YYmsJGlEPTB;NECgcm0> MVqxPFgzQTN|NB?=
mouse P388 cells NYTPd2QzS3m2b4TvfIlkyqCjc4PhfS=> MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDQN|g5KGOnbHzzJIFnfGW{IF3UWEBie3OjeTygTWM2OD12NTDuUS=> Mk\PNVg5Ojl|M{S=
A427 human lung carcinoma MVfQdo9tcW[ncnH0bY9vKGG|c3H5 NW\ETFJjSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkhdWWjc4Xy[YQh[WejaX7zeEBCPDJ5IHj1cYFvKGy3bnegZ4Fz[2mwb33hMEBKSzVyPUS5JI5O MUm5PFc3OTFz
human U251 cells MVvGeY5kfGmxbjDhd5NigQ>? NHOwcng3NTJ2IHi= MXjJcohq[mm2aX;uJI9nKHSxcH;pd49u\XKjc3WtNUBqdiCqdX3hckBWOjVzIHPlcIx{KGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhcHmyb4jpZU1qdmS3Y3XkJGhKTi1zYXzwbIEh[WOldX31cIF1cW:wIHnuJI52[2ynYYKg[Zh1emGldDDh[pRmeiB4IITvJFI1KGi{czDifUBqdW23bn;icI91KGGwYXz5d4l{NCCHQ{WwQVU1KG6P MlPYNlI{ODV4MUK=
human colon cancer cell line (WiDr) NVPqXVdQS3m2b4TvfIlkyqCjc4PhfS=> NEny[2VKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBkd2yxbjDjZY5k\XJiY3XscEBtcW6nIDjXbWRzMSxiSVO1NF02PiCwTR?= MYGxNVM{PDV4OR?=
human HepG2 cells M2jJOWN6fG:2b4jpZ:Kh[XO|YYm= MUe0JIRigXN? NHjvfmZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJ\XCJMjDj[YxteyCjZoTldkA1KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVYxKG6P Mn3DNVg2PTR7ME[=
human KB cells MonER5l1d3SxeHnjxsBie3OjeR?= MVq3NkBp M2D6d2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtDKGOnbHzzJIFnfGW{IEeyJIhzeyC|dXzmc5Jpd2SjbXnu[UBDKGOxbH;ybY1mfHKrYzDhd5NigSxiSVO1NF03Oi53IH7N NHPPcJQzPTByOES1Oi=>
human HCT8 cells NEfvUYdEgXSxdH;4bYPDqGG|c3H5 M2nKclMh\GG7cx?= NHftcoZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJS1R6IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9O|Ahdk1? M{HPO|IxOzl{NUS1
human GBM2 cells NWfoZXRXWHKxbHnm[ZJifGmxbjDhd5NigQ>? M3zE[lczKGh? MWDBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEeETUKgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IGfTWE0yKG2ndHjv[EwhUUN3ME2wMlE{KM7:TR?= MVKyOlM2PTV|Mh?=
SK-MEL-2 cells MYDDfZRwfG:6aXRCpIF{e2G7 M2rZ[lczKGh? M3T6WWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHNMNU2HTD2yJINmdGy|IHHmeIVzKDd{IHjyd{BjgSCjbHHtZZIh[my3ZTDhd5NigSxiSVO1NF0xNjF2IN88US=> Mn75NlE{PDF4N{S=
human IGROV1 cells MlHNR5l1d3SxeHnjxsBie3OjeR?= MYS3NkBp NH3GUnFEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBKT1KRVkGgZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KGGuYX3hdkBjdHWnIHHzd4F6NCCLQ{WwQVAvOTZizszN NFj0UmUzOTN2MU[3OC=>
human U87 cells NIXhOFFRem:uaX\ldoF1cW:wIHHzd4F6 MX60PEBp M2jhc2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iVUi3JINmdGy|IHHzd4V{e2WmIHHzJIdzd3e2aDDpcohq[mm2aX;uJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xOkDPxE1? NX:3O445OjR6Mk[4NVg>
human HT1080 cells NUnkSZhPWHKxbHnm[ZJifGmxbjDhd5NigQ>? Mn3vOFghcA>? M2PKdGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSxNFgxKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGmwY4XiZZRm\CCob4KgOFghcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFnDOVA:OC5zODFOwG0> MUKyOlQxQDhzNR?=
human Hep3B cells M3nscXBzd2yrZnXyZZRqd25iYYPzZZk> M1zXVVczKGh? M4jNNmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXwN2Ih[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IGjUWEBie3OjeTygS2k2OD1yLkKyJO69VQ>? MXqxPVc6Pjl3Nh?=
human GBM3 cells MWTQdo9tcW[ncnH0bY9vKGG|c3H5 NWjEN3VpPzJiaB?= NUDJb5dGSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDHRm0{KGOnbHzzJIF{e2W|c3XkJIF{KHKnZIXjeIlwdiCrbjDj[YxtKH[rYXLpcIl1gSCrbnP1ZoF1\WRiZn;yJFczKGi{czDifUBYW1RvMTDt[ZRpd2RuIFnDOVA:OC5|ODFOwG0> NWG3WZpoOjZ|NUW1N|I>
human KBVIN cells Mnq3R5l1d3SxeHnjxsBie3OjeR?= NEjsWZI4OiCq NWH2UZdFS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hU0KYSV6gZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NF0xNjRizszN MVOyOVQ{QDd4OR?=
human GBM1 cells NXexNYl7WHKxbHnm[ZJifGmxbjDhd5NigQ>? MVO3NkBp MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEeETUGgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJIlvKGOnbHygeoli[mmuaYT5JIlv[3WkYYTl[EBnd3JiN{KgbJJ{KGK7IGfTWE0yKG2ndHjv[EwhUUN3ME2wMlQ3KM7:TR?= MXOyOlM2PTV|Mh?=
human U937 cells MlzjR5l1d3SxeHnjxsBie3OjeR?= NVj5clVJPDhiaB?= MorTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWVk{PyClZXzsd{BmgHC{ZYPzbY5oKHB3MzDteZRidnRiYX\0[ZIhPDhiaILzJIJ6KFOUQjDhd5NigSExvJygTWM2OD1zLkGg{txO NWLwZlZFOTl5MUWzNVk>

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Animals inoculate s.c. with DU-145 Luc cells and then treated with Topotecan demonstrates significant tumor growth and regression as measured with calipers and luminescent imaging. The correlation coefficient is 0.75 for the control untreated group and 0.93 for the Topotecan-treated group. Similarly, tumor progression and regression are measurable using luminescent imaging for untreated and Topotecan-treated mice inoculated i.p. with MCF-7 Luc cells. [1] Topotecan elicited potent antileukemic activity in severe combined immune-deficiency (SCID) mouse models of human poor prognosis ALL. Topotecan markedly improved event-free survival of SCID mice challenged with otherwise fatal doses of humaln leukemia cells at systemic drug exposure levels. [2] Gliomas preferentially express TRAIL R2 and that treatment with Topotecan significantly up-regulates its expression. [3]

お薦めの試験操作(参考用のみ)

細胞試験:

[1]

+ 展開
  • 細胞株: MCF-7 Luc and DU-145 Luc cells
  • 濃度: 0 μg/mL - 0.692 μg/mL
  • 反応時間: 96 hours
  • 実験の流れ:

    Topotecan is dissolved in sterile water to a stock concentration of 1 mg/mL, diluted to 6 μg/mL in cultured medium and then serially diluted 1:4 in opaque, white tissue culture-treated microplates to a final volume of 0.1 mL/well. MCF-7 Luc and DU-145 Luc cells are resuspended in 3×104 cells/mL in DMEM with high glucose containing 10% FBS and 0.5 mg/mL Geneticin; 100 μL of cells are added in each well. Plates are incubated for 4 days at 37 °C in 95% humidity/5% CO2. After incubation, 0.05 mL of 0.1 M HEPES buffer (pH 7.9) containing 50 μg/mL D-luciferin is added to each well. After incubation at room temperature for 10 minutes, the culture microplate is measured in a microplate luminometer and a molecular light imager. Results obtained with the microplate luminometer are calculated using no inhibition control wells without exogenous drug and maximum inhibition control wells containing ATP inhibitor. Results for the molecular light imager are similarly calculated using values obtained with a 5 minutes luminescent imager.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Mice with MCF-7 Luc or DU-145 Luc cells
  • 製剤: PBS
  • 投薬量: 0.25 mg/mL
  • 投与方法: Administered via i.p.
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 91 mg/mL (198.72 mM)
Water 91 mg/mL (198.72 mM)
Ethanol Insoluble
体内 順序で溶剤を入れること:
Saline
30 mg/mL

* 溶解度検測はSelleck技術部門によって行いますので、文献より提供された溶解度と差異がある可能性がありますが、生産工芸と不同ロット(lot)で起きる正常な現象ですから、ご安心ください。

化学情報

分子量 457.91
化学式

C23H23N3O5.HCl

CAS No. 119413-54-6
保管
別名 NSC609699, Nogitecan HCl, SKFS 104864A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9, 2007 Phase 1
NCT00117013 Completed Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) June 28, 2005 Phase 1
NCT02980809 Not yet recruiting Small Cell Lung Cancer First Hospitals affiliated to the China PLA General Hospital March 2017 Phase 2
NCT02963090 Not yet recruiting Small Cell Lung Cancer Alliance Foundation Trials, LLC.|Merck Sharp & Dohme Corp. December 2016 Phase 2
NCT02348398 Withdrawn Cervical Cancer M.D. Anderson Cancer Center|GlaxoSmithKline August 2016 Phase 2
NCT02822157 Not yet recruiting Ovarian Epithelial Cancer Universitaire Ziekenhuizen Leuven|AstraZeneca August 2016 Phase 2

技術サポート

ストックの作り方、阻害剤の保管する方法、細胞実験や動物実験に注意すべきな点を全部含めており、製品を取扱う時よくあった質問に対して取扱説明書でお答えいたします。

Handling Instructions

他の質問がある場合は、お気軽くお問合せください。

  • * 必須

よくある質問(FAQ)

  • 問題1:

    I would like get the compound for mice intraperitoneally injection, What would you recommend to improve solubility? What could I use as solvent (%v?) that is nontoxic (unlike Methanol) and could be injected into mice intraperitoneally?

  • 回答:

    Topotecan HCl is generally prepared by Saline for I.P. administration.

Topoisomerase信号経路図

相関Topoisomerase製品

Tags: Topotecan HClを買う | Topotecan HCl ic50 | Topotecan HCl供給者 | Topotecan HClを購入する | Topotecan HCl費用 | Topotecan HCl生産者 | オーダーTopotecan HCl | Topotecan HCl化学構造 | Topotecan HCl分子量 | Topotecan HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID